PortfoliosLab logoPortfoliosLab logo
GSK.L vs. SGSOY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GSK.L vs. SGSOY - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in GlaxoSmithKline plc (GSK.L) and SGS SA (SGSOY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

GSK.L is traded in GBp, while SGSOY is traded in USD. To make them comparable, the SGSOY values have been converted to GBp using the latest available exchange rates.

Returns By Period

In the year-to-date period, GSK.L achieves a 10.61% return, which is significantly higher than SGSOY's 2.59% return. Over the past 10 years, GSK.L has underperformed SGSOY with an annualized return of 6.03%, while SGSOY has yielded a comparatively higher 6.69% annualized return.


GSK.L

1D
1.10%
1M
6.15%
YTD
10.61%
6M
10.61%
1Y
32.87%
3Y*
17.81%
5Y*
6.60%
10Y*
6.03%

SGSOY

1D
-0.54%
1M
4.33%
YTD
2.59%
6M
6.10%
1Y
12.69%
3Y*
7.71%
5Y*
2.50%
10Y*
6.69%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GSK.L vs. SGSOY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GSK.L
GlaxoSmithKline plc
10.61%41.46%-3.51%4.94%-25.94%26.66%-20.76%25.32%19.02%-10.82%
SGSOY
SGS SA
2.59%10.65%22.25%-8.85%-20.88%17.18%9.22%18.67%-6.78%23.89%

Correlation

The correlation between GSK.L and SGSOY is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.24

Correlation (3Y)
Calculated over the trailing 3-year period

0.19

Correlation (5Y)
Calculated over the trailing 5-year period

0.16

Correlation (10Y)
Calculated over the trailing 10-year period

0.24

Correlation (All Time)
Calculated using the full available price history since Jul 13, 2007

0.23

Fundamentals

Market Cap

GSK.L:

£80.83B

SGSOY:

$21.59B

EPS

GSK.L:

£1.42

SGSOY:

CHF 0.65

PE Ratio

GSK.L:

13.93

SGSOY:

13.72

PEG Ratio

GSK.L:

0.31

SGSOY:

7.42

PS Ratio

GSK.L:

2.48

SGSOY:

1.25

PB Ratio

GSK.L:

4.53

SGSOY:

19.09

Total Revenue (TTM)

GSK.L:

£32.78B

SGSOY:

CHF 13.71B

Gross Profit (TTM)

GSK.L:

£23.84B

SGSOY:

CHF 8.66B

EBITDA (TTM)

GSK.L:

£11.56B

SGSOY:

CHF 2.70B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GSK.L vs. SGSOY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GSK.L
GSK.L Risk / Return Rank: 7676
Overall Rank
GSK.L Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
GSK.L Sortino Ratio Rank: 7878
Sortino Ratio Rank
GSK.L Omega Ratio Rank: 7575
Omega Ratio Rank
GSK.L Calmar Ratio Rank: 7474
Calmar Ratio Rank
GSK.L Martin Ratio Rank: 7575
Martin Ratio Rank

SGSOY
SGSOY Risk / Return Rank: 5656
Overall Rank
SGSOY Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
SGSOY Sortino Ratio Rank: 5353
Sortino Ratio Rank
SGSOY Omega Ratio Rank: 5151
Omega Ratio Rank
SGSOY Calmar Ratio Rank: 5656
Calmar Ratio Rank
SGSOY Martin Ratio Rank: 6060
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GSK.L vs. SGSOY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK.L) and SGS SA (SGSOY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


GSK.LSGSOYDifference
Sharpe ratioReturn per unit of total volatility

+0.66

Sortino ratioReturn per unit of downside risk

+1.01

Omega ratioGain probability vs. loss probability

1.25

1.13

+0.12

Calmar ratioReturn relative to maximum drawdown

1.78

0.78

+1.00

Martin ratioReturn relative to average drawdown

4.57

2.11

+2.45

GSK.L vs. SGSOY - Sharpe Ratio Comparison

The current GSK.L Sharpe Ratio is 1.31, which is higher than the SGSOY Sharpe Ratio of 0.65. The chart below compares the historical Sharpe Ratios of GSK.L and SGSOY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

GSK.L vs. SGSOY - Drawdown Comparison

The maximum GSK.L drawdown since its inception was -42.39%, which is greater than SGSOY's maximum drawdown of -38.26%. Use the drawdown chart below to compare losses from any high point for GSK.L and SGSOY.


Loading charts...

Drawdown Indicators


GSK.LSGSOYDifference

Max Drawdown

Largest peak-to-trough decline

-42.39%

-38.26%

-4.13%

Max Drawdown (1Y)

Largest decline over 1 year

-18.35%

-16.30%

-2.05%

Max Drawdown (3Y)

Largest decline over 3 years

-27.42%

-20.25%

-7.17%

Max Drawdown (5Y)

Largest decline over 5 years

-42.39%

-30.82%

-11.57%

Max Drawdown (10Y)

Largest decline over 10 years

-42.39%

-30.82%

-11.57%

Current Drawdown

Current decline from peak

-11.02%

-7.07%

-3.95%

Average Drawdown

Average peak-to-trough decline

-12.78%

-10.02%

-2.76%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.93%

6.03%

+0.90%

Volatility

GSK.L vs. SGSOY - Volatility Comparison

GlaxoSmithKline plc (GSK.L) has a higher volatility of 6.10% compared to SGS SA (SGSOY) at 4.56%. This indicates that GSK.L's price experiences larger fluctuations and is considered to be riskier than SGSOY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GSK.LSGSOYDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.10%

4.56%

+1.54%

Volatility (6M)

Calculated over the trailing 6-month period

18.09%

14.26%

+3.83%

Volatility (1Y)

Calculated over the trailing 1-year period

25.04%

19.58%

+5.46%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

23.68%

21.14%

+2.54%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.09%

20.83%

+1.26%

Dividends

GSK.L vs. SGSOY - Dividend Comparison

GSK.L's dividend yield for the trailing twelve months is around 3.38%, less than SGSOY's 3.67% yield.


PositionTTM20252024202320222021202020192018201720162015
GSK.L
GlaxoSmithKline plc
3.38%3.51%4.53%3.84%5.30%4.93%5.90%4.45%5.31%5.99%4.88%5.77%
SGSOY
SGS SA
3.67%3.19%3.64%3.96%3.72%2.52%1.61%1.69%2.10%4.35%5.56%2.04%

Financials

GSK.L vs. SGSOY - Financials Comparison

This section allows you to compare key financial metrics between GlaxoSmithKline plc and SGS SA. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


3.00B4.00B5.00B6.00B7.00B8.00B9.00B20222023202420252026
7.63B
3.49B
(GSK.L) Total Revenue
(SGSOY) Total Revenue
Please note, different currencies. GSK.L values in GBP, SGSOY values in CHF

GSK.L vs. SGSOY - Profitability Comparison

The chart below illustrates the profitability comparison between GlaxoSmithKline plc and SGS SA over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%80.0%20222023202420252026
75.4%
37.9%
Portfolio components
GSK.L - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.

SGSOY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, SGS SA reported a gross profit of 1.32B and revenue of 3.49B. Therefore, the gross margin over that period was 37.9%.

GSK.L - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.

SGSOY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, SGS SA reported an operating income of 561.32M and revenue of 3.49B, resulting in an operating margin of 16.1%.

GSK.L - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.

SGSOY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, SGS SA reported a net income of 351.08M and revenue of 3.49B, resulting in a net margin of 10.1%.


Frequently Asked Questions


GSK.L and SGSOY have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for GSK.L and SGSOY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer